Latest Bsd Medical Corp (BSDM) Headlines
Global Ablation Technologies Market 2012-2016: Major Cancer Diseases that Use Ablation Technology Devices are Discussed in Detail
M2 - Mon Mar 10, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5z78kx/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. The analysts forecast the Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Ablation technology devices are used for various clinical applications and Cancer therapy, and accounted for the largest segment of the Global Ablation Technologies market. The key vendors dominating this market space include Boston Scientific Corp., Medtronic Inc., St.Jude Medical Inc., and Varian Medical Systems Inc. The other vendors mentioned in the report are Accuray Inc., Alcon Laboratories Inc., AngioDynamics Inc., Arthrocare Corp., Atricure Inc., ATS Medical Inc., Biosense Webster Inc., BSD Medical Corporation, C.R. Bard Inc., Candela Corp., CardioGenesis Corp., CermaVEIN SAS, ConMed Corporation, Covidien plc, EDAP TMS S.A., Elekta AB, Endo Health Solutions Inc., Galil Medical Ltd., HealthTronics Inc., Hologic Inc., Idoman Ltd., Maquet Holding GmbH and Co. KG (Gentinge AB group), Microsulis Medical Ltd, Misonix Inc., nContact Surgical Inc., Olympus Corp., Relievant Medsystems, Rhythmia Medical Inc., Smith and Nephew plc, Solta Medical Inc., Syneron Medical Ltd., TheraGenics Corp., Urologix Inc., VNUS Medical Technologies Inc., and Zeltiq Aesthetics Inc. Commenting on the report, an analyst from the Healthcare team said: One of the upcoming trends in the Global Ablation Technology market is the rapid advancements in technology using ablation technology devices. Although the market for ablation technology devices is at a mature stage, the level of technology is still at a nascent stage; more devices with cutting-edge technology are expected to be introduced in the near future. Recently, laser ablation devices have been introduced to perform precise ablation of body tissue; these devices run on a laser energy transmission mechanism using fiber optics. This kind of device is used in transmyocardial revascularization and angioplasty. Another major advancement is the usage of catheter ablation for atrial fibrillation, which is commonly used to control tachy-arrhythmia. Thus, the rapid advancement in technology is an emerging trend that has a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/5z...l_ablation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSD Medical's Fiscal Second Quarter Revenues Increase 106% to $1.7 Million
Business Wire - Wed Mar 05, 2:14PM CST
--Company to Report Full Second Quarter Financial Results and Will Hold an Investment Community Conference Call on April 9
BSD Medical Reports on Continued Sales Momentum by Terumo for the MicroThermX(R) Microwave System
Business Wire - Mon Mar 03, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported continued sales momentum by Terumo on the distribution of the MicroThermX(R) Microwave Ablation System (MicroThermX). BSD's exclusive, multimillion dollar agreement with Terumo Europe NV (Terumo) covers distribution of the MicroThermX in more than 100 countries, including Europe, Western Asia and Africa, with a market potential that exceeds $1 billion.
BSD Medical Announces Taiwan Food and Drug Administration Marketing Approval for the BSD-2000
Business Wire - Tue Feb 25, 10:06AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that BSD's exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden) has obtained Taiwan Food and Drug Administration (TFDA) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000). Linden is a leading distributor of sophisticated medical devices in Taiwan. Linden has committed to an initial purchase of four BSD-2000 Hyperthermia Systems for market introduction. BSD will ship the systems in the current fiscal year ending August 31, 2014.
BSD Medical Corporation expects TFDA's marketing and import license for the BSD-2000
M2 - Fri Feb 07, 6:04AM CST
Medical systems company BSD Medical Corporation (BSDM) reported on Thursday the Taiwan Food and Drug Administration's (TFDA) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) is in process and the import permit is expected to be issued in the near future.
BSD Medical Announces Taiwan Food and Drug Administration Marketing and Import License Approval for the BSD-2000 is in Process
Business Wire - Thu Feb 06, 2:46PM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that BSD's exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden) has informed BSD that the Taiwan Food and Drug Administration (TFDA) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) is in process and the import permit is expected to be issued in the near future. Linden is a leading distributor of sophisticated medical devices in Taiwan. Linden has committed to an initial purchase of four (4) BSD-2000 Hyperthermia Systems. BSD will commence shipping systems as soon as the import license is issued.
BSD Medical's MicroThermX(R) Featured in a Presentation at Clinical Interventional Oncology Conference
Business Wire - Thu Feb 06, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today announced that the Company's MicroThermX Microwave Ablation System (MicroThermX) technology was presented in a session at the 6th Annual Symposium on Clinical Interventional Oncology (CIO) held in Miami.
BSD Medical Announces Sale of the MicroThermX(R) Microwave Ablation Products in Egypt
Business Wire - Tue Jan 28, 8:15AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company has received a significant purchase order for MicroThermX Microwave Ablation (MicroThermX) products from its exclusive distributor in Egypt, Misr Sinai Company (MCS). MCS is a leading medical specialty distributor in Egypt headquartered in Cairo.
BSD Medical Announces First Quarter Fiscal 2014 Financial Results
Business Wire - Thu Jan 09, 8:14AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported financial results for its first quarter ended November 30, 2013.
BSD Medical reports divestiture of BSD-500 Hyperthermia System to Loyola University Medical Center
M2 - Wed Dec 18, 5:56AM CST
Cancer heat therapy company BSD Medical Corporation (NasdaqGM:BSDM) reported on Tuesday the sale of its BSD-500 Hyperthermia System (BSD-500) for an undisclosed amount.
BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Loyola University Medical Center
Business Wire - Tue Dec 17, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that Loyola University Medical Center (LUMC) in Maywood, Illinois has purchased a BSD-500 Hyperthermia System (BSD-500). Loyola University Medical Center (LUMC) is the core of the Loyola University Health System and one of the nation's leading academic medical centers. In the U.S. News 2013-14 hospital rankings, Loyola's Cancer program was rated among the top 25 percent of hospitals in cancer treatment. LUMC is nationally recognized for providing technologically advanced treatments and for promoting patient safety. The purchase of the BSD-500 by this prestigious medical center is further evidence of the growing use of hyperthermia therapy in the United States and will increase the number of patients who will have access to innovative hyperthermia treatment.
BSD Medical Signs Distribution Agreement with and Ships MicroThermX(R) Microwave Ablation Products to Active Medical Inc.
Business Wire - Wed Dec 11, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has signed an agreement with Active Medical, Inc. (Active) for the sales and distribution of the MicroThermX Microwave Ablation (MicroThermX) line of products. Pursuant to the agreement, BSD recently commenced shipment of MicroThermX systems and synchronous phased array disposable antennas to Active.
BSD Medical Announces Sale of the MicroThermX(R) Microwave Ablation Systems in Turkey
Business Wire - Thu Dec 05, 8:15AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company has received a purchase order for multiple MicroThermX Microwave Ablation (MicroThermX) systems and antennas from its exclusive distributor in Turkey, ADA Medikal (ADA). This is the second order for multiple MicroThermX Microwave Ablation (MicroThermX) systems and antennas from ADA. ADA is a leading medical specialty distributor in Turkey with offices in the nation's major metropolitan areas.
BSD Medical's System Featured at Symposium on Hyperthermia for the Treatment of Cancer in Turkey
Business Wire - Thu Nov 21, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company's BSD-2000-3D/MR System was featured at a symposium focused on the use of hyperthermia in the treatment of cancer held in Ankara, Turkey. The symposium, "MR Kontrollu Derin Bolgesel Hipertermi (MR controlled deep regional hyperthermia)," was hosted by Meyra Saglik, BSD's distributor in Turkey, and chaired by Professor Dr. M. Kadri Altundag, MD, PhD, head of medical oncology department of Hacettepe University in Ankara.
BSD Medical Receives Order for a BSD-2000/3D/MR Image Guided Hyperthermia System for Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands
Business Wire - Tue Nov 19, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has received a purchase order from Dr. Sennewald Medizintechnik GmbH for a BSD-2000/3D/MR Image Guided Hyperthermia System (BSD-2000/3D/MR) that will be installed at the Erasmus MC Cancer Institute, location Daniel den Hoed. The BSD-2000/3D/MR system integrates a BSD-2000/3D Hyperthermia System with Magnetic Resonance (MR) imaging to deliver targeted image guided hyperthermia therapy, while simultaneously providing non-invasive imaging of the diseased tissue as well as the surrounding healthy tissue. The magnetic resonance images are color graded to show temperature changes in the treatment area during hyperthermia therapy.
BSD Medical Corporation Announces Investor & Analyst Update Conference Call
Business Wire - Thu Nov 14, 11:07AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD), a leading provider of medical systems that treat cancer and benign diseases using heat, today announced that it will host an Investor & Analyst Update Call and live webcast on Wednesday, December 4, 2013 at 2:00 p.m. Eastern time/12:00 p.m. Mountain time. The call will be hosted by Harold Wolcott, President and William Barth, Chief Financial Officer.
BSD Medical Announces Fiscal Year 2013 Financial Results
Business Wire - Thu Nov 07, 8:15AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported financial results for its fiscal year ended August 31, 2013.
BSD Medical Announces Symposium on Hyperthermia for the Treatment of Cancer at N.N. Blokhin Cancer Center in Russia to Feature BSD's Hyperthermia Systems
Business Wire - Fri Nov 01, 8:15AM CDT
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company's hyperthermia systems will be featured at a symposium focused on image guided hyperthermia treatment of cancer. The symposium will be hosted by the N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences (Blokhin Cancer Center), the leading comprehensive cancer center in Russia, and chaired by Professor Mikhail Davydov M.D. Ph.D., President of the Russian Academy of Medical Sciences and Director of the Blokhin Cancer Center. The symposium, "The Role of Hybrid Hyperthermia in the Therapy of Oncological Diseases," will be held on Nov. 29, 2013, in Moscow, Russia. The Blokhin Cancer Center comprises four separate Institutes, including a 1,600-bed hospital devoted to cancer patients. It is one of the largest hospitals in Europe and is part of the American-Russian Cancer Alliance, which also includes prominent U.S. cancer treatment centers. The U.S. National Cancer Institute (NCI) provides the infrastructure for the Alliance. The symposium was arranged following a request from Blokhin Cancer Center to host the hyperthermia symposium. The conference will feature presentations by leading scientists of the latest research and clinical results on hyperthermia, and BSD's equipment will be featured prominently in these presentations.
BSD Medical Announces First Symposium on Hyperthermia Treatment of Cancer in Taiwan to Feature BSD-2000 Hyperthermia System
Business Wire - Wed Oct 30, 8:15AM CDT
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company's BSD-2000 Hyperthermia System (BSD-2000) will be featured at the first symposium on hyperthermia treatment of cancer held in Taiwan. Taipei Medical University and Taipei City Wan Fang Hospital will jointly host the "2013 Taipei International Symposium on Cancer Hyperthermia" on Sunday, November 3, at the Taipei Medical University. BSD's exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden), has been invited to present on the BSD-2000 at the symposium.
BSD Reports Increasing European Market Penetration by Terumo for MicroThermX(R) Microwave Ablation System
Business Wire - Thu Oct 24, 8:15AM CDT
BSD Medical Corporation (NASDAQ: BSDM) ("Company" or "BSD") today reported that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, has already introduced the MicroThermX(R) Microwave Ablation System (MicroThermX) into the major markets in Europe, including Germany, France and Spain.
Global Ablation Technologies Market 2012-2016: Major Cancer Diseases that Use Ablation Technology Devices are Discussed in Detail
M2 - Mon Mar 10, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5z78kx/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. The analysts forecast the Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Ablation technology devices are used for various clinical applications and Cancer therapy, and accounted for the largest segment of the Global Ablation Technologies market. The key vendors dominating this market space include Boston Scientific Corp., Medtronic Inc., St.Jude Medical Inc., and Varian Medical Systems Inc. The other vendors mentioned in the report are Accuray Inc., Alcon Laboratories Inc., AngioDynamics Inc., Arthrocare Corp., Atricure Inc., ATS Medical Inc., Biosense Webster Inc., BSD Medical Corporation, C.R. Bard Inc., Candela Corp., CardioGenesis Corp., CermaVEIN SAS, ConMed Corporation, Covidien plc, EDAP TMS S.A., Elekta AB, Endo Health Solutions Inc., Galil Medical Ltd., HealthTronics Inc., Hologic Inc., Idoman Ltd., Maquet Holding GmbH and Co. KG (Gentinge AB group), Microsulis Medical Ltd, Misonix Inc., nContact Surgical Inc., Olympus Corp., Relievant Medsystems, Rhythmia Medical Inc., Smith and Nephew plc, Solta Medical Inc., Syneron Medical Ltd., TheraGenics Corp., Urologix Inc., VNUS Medical Technologies Inc., and Zeltiq Aesthetics Inc. Commenting on the report, an analyst from the Healthcare team said: One of the upcoming trends in the Global Ablation Technology market is the rapid advancements in technology using ablation technology devices. Although the market for ablation technology devices is at a mature stage, the level of technology is still at a nascent stage; more devices with cutting-edge technology are expected to be introduced in the near future. Recently, laser ablation devices have been introduced to perform precise ablation of body tissue; these devices run on a laser energy transmission mechanism using fiber optics. This kind of device is used in transmyocardial revascularization and angioplasty. Another major advancement is the usage of catheter ablation for atrial fibrillation, which is commonly used to control tachy-arrhythmia. Thus, the rapid advancement in technology is an emerging trend that has a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/5z...l_ablation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSD Medical's Fiscal Second Quarter Revenues Increase 106% to $1.7 Million
Business Wire - Wed Mar 05, 2:14PM CST
--Company to Report Full Second Quarter Financial Results and Will Hold an Investment Community Conference Call on April 9
BSD Medical Reports on Continued Sales Momentum by Terumo for the MicroThermX(R) Microwave System
Business Wire - Mon Mar 03, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported continued sales momentum by Terumo on the distribution of the MicroThermX(R) Microwave Ablation System (MicroThermX). BSD's exclusive, multimillion dollar agreement with Terumo Europe NV (Terumo) covers distribution of the MicroThermX in more than 100 countries, including Europe, Western Asia and Africa, with a market potential that exceeds $1 billion.
BSD Medical Announces Taiwan Food and Drug Administration Marketing Approval for the BSD-2000
Business Wire - Tue Feb 25, 10:06AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that BSD's exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden) has obtained Taiwan Food and Drug Administration (TFDA) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000). Linden is a leading distributor of sophisticated medical devices in Taiwan. Linden has committed to an initial purchase of four BSD-2000 Hyperthermia Systems for market introduction. BSD will ship the systems in the current fiscal year ending August 31, 2014.
BSD Medical Corporation expects TFDA's marketing and import license for the BSD-2000
M2 - Fri Feb 07, 6:04AM CST
Medical systems company BSD Medical Corporation (BSDM) reported on Thursday the Taiwan Food and Drug Administration's (TFDA) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) is in process and the import permit is expected to be issued in the near future.
BSD Medical Announces Taiwan Food and Drug Administration Marketing and Import License Approval for the BSD-2000 is in Process
Business Wire - Thu Feb 06, 2:46PM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that BSD's exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden) has informed BSD that the Taiwan Food and Drug Administration (TFDA) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) is in process and the import permit is expected to be issued in the near future. Linden is a leading distributor of sophisticated medical devices in Taiwan. Linden has committed to an initial purchase of four (4) BSD-2000 Hyperthermia Systems. BSD will commence shipping systems as soon as the import license is issued.
BSD Medical's MicroThermX(R) Featured in a Presentation at Clinical Interventional Oncology Conference
Business Wire - Thu Feb 06, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today announced that the Company's MicroThermX Microwave Ablation System (MicroThermX) technology was presented in a session at the 6th Annual Symposium on Clinical Interventional Oncology (CIO) held in Miami.
BSD Medical Announces Sale of the MicroThermX(R) Microwave Ablation Products in Egypt
Business Wire - Tue Jan 28, 8:15AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company has received a significant purchase order for MicroThermX Microwave Ablation (MicroThermX) products from its exclusive distributor in Egypt, Misr Sinai Company (MCS). MCS is a leading medical specialty distributor in Egypt headquartered in Cairo.
BSD Medical Announces First Quarter Fiscal 2014 Financial Results
Business Wire - Thu Jan 09, 8:14AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported financial results for its first quarter ended November 30, 2013.
BSD Medical reports divestiture of BSD-500 Hyperthermia System to Loyola University Medical Center
M2 - Wed Dec 18, 5:56AM CST
Cancer heat therapy company BSD Medical Corporation (NasdaqGM:BSDM) reported on Tuesday the sale of its BSD-500 Hyperthermia System (BSD-500) for an undisclosed amount.
BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Loyola University Medical Center
Business Wire - Tue Dec 17, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that Loyola University Medical Center (LUMC) in Maywood, Illinois has purchased a BSD-500 Hyperthermia System (BSD-500). Loyola University Medical Center (LUMC) is the core of the Loyola University Health System and one of the nation's leading academic medical centers. In the U.S. News 2013-14 hospital rankings, Loyola's Cancer program was rated among the top 25 percent of hospitals in cancer treatment. LUMC is nationally recognized for providing technologically advanced treatments and for promoting patient safety. The purchase of the BSD-500 by this prestigious medical center is further evidence of the growing use of hyperthermia therapy in the United States and will increase the number of patients who will have access to innovative hyperthermia treatment.
BSD Medical Signs Distribution Agreement with and Ships MicroThermX(R) Microwave Ablation Products to Active Medical Inc.
Business Wire - Wed Dec 11, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has signed an agreement with Active Medical, Inc. (Active) for the sales and distribution of the MicroThermX Microwave Ablation (MicroThermX) line of products. Pursuant to the agreement, BSD recently commenced shipment of MicroThermX systems and synchronous phased array disposable antennas to Active.
BSD Medical Announces Sale of the MicroThermX(R) Microwave Ablation Systems in Turkey
Business Wire - Thu Dec 05, 8:15AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company has received a purchase order for multiple MicroThermX Microwave Ablation (MicroThermX) systems and antennas from its exclusive distributor in Turkey, ADA Medikal (ADA). This is the second order for multiple MicroThermX Microwave Ablation (MicroThermX) systems and antennas from ADA. ADA is a leading medical specialty distributor in Turkey with offices in the nation's major metropolitan areas.
BSD Medical's System Featured at Symposium on Hyperthermia for the Treatment of Cancer in Turkey
Business Wire - Thu Nov 21, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company's BSD-2000-3D/MR System was featured at a symposium focused on the use of hyperthermia in the treatment of cancer held in Ankara, Turkey. The symposium, "MR Kontrollu Derin Bolgesel Hipertermi (MR controlled deep regional hyperthermia)," was hosted by Meyra Saglik, BSD's distributor in Turkey, and chaired by Professor Dr. M. Kadri Altundag, MD, PhD, head of medical oncology department of Hacettepe University in Ankara.
BSD Medical Receives Order for a BSD-2000/3D/MR Image Guided Hyperthermia System for Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands
Business Wire - Tue Nov 19, 8:15AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has received a purchase order from Dr. Sennewald Medizintechnik GmbH for a BSD-2000/3D/MR Image Guided Hyperthermia System (BSD-2000/3D/MR) that will be installed at the Erasmus MC Cancer Institute, location Daniel den Hoed. The BSD-2000/3D/MR system integrates a BSD-2000/3D Hyperthermia System with Magnetic Resonance (MR) imaging to deliver targeted image guided hyperthermia therapy, while simultaneously providing non-invasive imaging of the diseased tissue as well as the surrounding healthy tissue. The magnetic resonance images are color graded to show temperature changes in the treatment area during hyperthermia therapy.
BSD Medical Corporation Announces Investor & Analyst Update Conference Call
Business Wire - Thu Nov 14, 11:07AM CST
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD), a leading provider of medical systems that treat cancer and benign diseases using heat, today announced that it will host an Investor & Analyst Update Call and live webcast on Wednesday, December 4, 2013 at 2:00 p.m. Eastern time/12:00 p.m. Mountain time. The call will be hosted by Harold Wolcott, President and William Barth, Chief Financial Officer.
BSD Medical Announces Fiscal Year 2013 Financial Results
Business Wire - Thu Nov 07, 8:15AM CST
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today reported financial results for its fiscal year ended August 31, 2013.
BSD Medical Announces Symposium on Hyperthermia for the Treatment of Cancer at N.N. Blokhin Cancer Center in Russia to Feature BSD's Hyperthermia Systems
Business Wire - Fri Nov 01, 8:15AM CDT
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company's hyperthermia systems will be featured at a symposium focused on image guided hyperthermia treatment of cancer. The symposium will be hosted by the N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences (Blokhin Cancer Center), the leading comprehensive cancer center in Russia, and chaired by Professor Mikhail Davydov M.D. Ph.D., President of the Russian Academy of Medical Sciences and Director of the Blokhin Cancer Center. The symposium, "The Role of Hybrid Hyperthermia in the Therapy of Oncological Diseases," will be held on Nov. 29, 2013, in Moscow, Russia. The Blokhin Cancer Center comprises four separate Institutes, including a 1,600-bed hospital devoted to cancer patients. It is one of the largest hospitals in Europe and is part of the American-Russian Cancer Alliance, which also includes prominent U.S. cancer treatment centers. The U.S. National Cancer Institute (NCI) provides the infrastructure for the Alliance. The symposium was arranged following a request from Blokhin Cancer Center to host the hyperthermia symposium. The conference will feature presentations by leading scientists of the latest research and clinical results on hyperthermia, and BSD's equipment will be featured prominently in these presentations.
BSD Medical Announces First Symposium on Hyperthermia Treatment of Cancer in Taiwan to Feature BSD-2000 Hyperthermia System
Business Wire - Wed Oct 30, 8:15AM CDT
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company's BSD-2000 Hyperthermia System (BSD-2000) will be featured at the first symposium on hyperthermia treatment of cancer held in Taiwan. Taipei Medical University and Taipei City Wan Fang Hospital will jointly host the "2013 Taipei International Symposium on Cancer Hyperthermia" on Sunday, November 3, at the Taipei Medical University. BSD's exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden), has been invited to present on the BSD-2000 at the symposium.
BSD Reports Increasing European Market Penetration by Terumo for MicroThermX(R) Microwave Ablation System
Business Wire - Thu Oct 24, 8:15AM CDT
BSD Medical Corporation (NASDAQ: BSDM) ("Company" or "BSD") today reported that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, has already introduced the MicroThermX(R) Microwave Ablation System (MicroThermX) into the major markets in Europe, including Germany, France and Spain.
